Sera Prognostics - IR Website

Home

News

Month Year

Investor Alerts

September 28

SERA PROGNOSTICS APPOINTS DR. PAUL KEARNEY AS CHIEF DATA OFFICER

Brings extensive data science, bioinformatics and proteomics experience to foster further product innovation and informed healthcare insights into pregnancy

Salt Lake City, Sep. 28, 2021 (GLOBE NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...

Read More
September 15

SERA PROGNOSTICS APPOINTS DR. MICHAEL R. FOLEY AS CHIEF MEDICAL OFFICER

Salt Lake City, Sep. 15, 2021 (GLOBE NEWSWIRE) —Sera Prognostics Inc., The Pregnancy Company™ (NASDAQ: SERA), focused on improving maternal and neonatal health by providing innovative...

Read More
September 14

SERA PROGNOSTICS ANNOUNCES PUBLICATION OF HEALTH ECONOMIC ANALYSIS SUPPORTING PRETRM® TEST-AND-TREAT STRATEGY TO IMPROVE MATERNAL AND INFANT HEALTH

Publication illustrates clinical benefit of combining PreTRM® testing with evidence-based interventions to improve neonatal health and reduce total health costs

Salt Lake City – September 14, 2021 – Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information...

Read More
September 13

SERA PROGNOSTICS TO PRESENT AT OPPENHEIMER FALL HEALTHCARE LIFE SCIENCES & MED TECH SUMMIT

Salt Lake City – September 13, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
August 30

SERA PROGNOSTICS REPORTS SECOND QUARTER 2021 FINANCIAL RESULTS

Salt Lake City – August 30, 2021 – Sera Prognostics Inc., The Pregnancy Company™ (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
August 17

Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility

Study demonstrates positive impact of the company’s PreTRM® test and treat strategy on improving neonatal healthcare

SALT LAKE CITY, Aug. 17, 2021 (GLOBE NEWSWIRE) — Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
July 14

Sera Prognostics Announces Pricing of Initial Public Offering

Salt Lake City – July 14, 2021 – Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker...

Read More
May 19

Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth

– The PreTRM® Test Is Designed to Build a Foundation for Healthy Communities One Baby at a Time

SALT LAKE CITY, May 19, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative pregnancy...

Read More
May 18

EVALUATION OF HEALTH AND ECONOMIC BENEFIT OF THE PRETRM® TEST-AND-TREAT STRATEGY TO IMPROVE MATERNAL AND INFANT HEALTH AMONG COMMERCIALLY INSURED IN THE US

– Data presented at the ISPOR 2021 Conference illustrating clinical benefit as well as cost savings

Salt Lake City – May 18, 2021 – Sera Prognostics Inc., The Pregnancy Company™, focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to...

Read More
April 28

Sera Prognostics Completes $100 Million Series E Financing

– Several prominent healthcare-focused institutional investors fund Sera to expand commercialization of the PreTRM® Test –

SALT LAKE CITY, April 28, 2021 (GLOBE NEWSWIRE) — Sera Prognostics, Inc., The Pregnancy Company® (“Sera”), focused on improving maternal and neonatal health by providing innovative...

Read More

Show per page

Email Alerts